The Current State of TRT
Testosterone replacement therapy (TRT) has experienced a dramatic surge in prescriptions over the past two decades. In the United States alone, testosterone prescriptions increased more than 300% between 2001 and 2013. This growth has been driven by increased awareness of hypogonadism (low testosterone), direct-to-consumer advertising, and the expansion of telehealth platforms specializing in hormone optimization.
Despite this widespread adoption, TRT remains a topic of legitimate medical debate. The published literature presents a nuanced picture — clear benefits for appropriately diagnosed patients alongside genuine considerations that require careful monitoring and management. This article examines both sides of the evidence objectively.
Diagnosing Low Testosterone
Before examining the pros and cons of TRT, it is important to understand what constitutes low testosterone and how it is diagnosed. The Endocrine Society defines male hypogonadism as a clinical syndrome resulting from failure of the testes to produce physiological levels of testosterone and/or a normal number of sperm, combined with symptoms consistent with testosterone deficiency.
Diagnosis requires both biochemical evidence (typically total testosterone below 300 ng/dL on two morning measurements) and the presence of clinical symptoms. Importantly, symptoms alone without biochemical confirmation — or low lab values without symptoms — do not meet the standard diagnostic criteria.
The Benefits of TRT
Body Composition
The evidence for TRT's effect on body composition is among the most robust in the literature. A meta-analysis by Corona et al. (2016) examining 59 randomized controlled trials found that TRT consistently reduced total body fat mass (average -1.6 kg), reduced waist circumference (average -2.2 cm), and increased lean body mass (average +1.6 kg). These effects were most pronounced in men with the lowest baseline testosterone levels and those with metabolic syndrome or type 2 diabetes.
The mechanisms are well-understood: testosterone promotes protein synthesis in skeletal muscle while simultaneously increasing lipolysis (fat breakdown) and inhibiting lipogenesis (fat formation). It also upregulates androgen receptors in muscle tissue, creating a positive feedback loop for muscle protein accretion.
Bone Density
Testosterone plays a critical role in maintaining bone mineral density in men. Both directly, through androgen receptors on osteoblasts, and indirectly, through aromatization to estradiol (which inhibits osteoclast-mediated bone resorption). Studies have consistently shown that TRT increases bone mineral density, particularly in the lumbar spine and femoral neck, in hypogonadal men.
This effect is clinically significant because male osteoporosis is underrecognized and undertreated, yet men account for approximately 30% of hip fractures, with mortality rates higher than in women following fracture.
Metabolic Health
Research has demonstrated significant metabolic improvements with TRT in hypogonadal men:
- Insulin Sensitivity: Multiple studies show improved insulin sensitivity and reduced fasting glucose levels with TRT, particularly in men with metabolic syndrome.
- Lipid Profile: TRT typically reduces total cholesterol and LDL cholesterol, though effects on HDL are variable across studies.
- Glycemic Control: In men with type 2 diabetes and hypogonadism, TRT has been associated with improved HbA1c levels.
Sexual Function
Improvement in sexual function is often the primary motivation for seeking TRT. Studies consistently demonstrate improvements in libido, erectile function, and overall sexual satisfaction. The Testosterone Trials (TTrials), a large coordinated series of seven randomized controlled trials, confirmed that testosterone treatment improved sexual activity and sexual desire in older men with low testosterone.
Mood and Cognitive Function
The relationship between testosterone and psychological well-being is well-documented. TRT in hypogonadal men has been associated with improvements in depressive symptoms, energy levels, motivation, and overall quality of life. Some studies also suggest improvements in spatial cognition and verbal memory, though the evidence for cognitive effects is less consistent than for mood benefits.
Cardiovascular Markers
This is an area where the evidence has evolved significantly. The TRAVERSE trial (Lincoff et al., NEJM 2023) — the largest cardiovascular safety trial of testosterone therapy ever conducted — enrolled 5,246 men aged 45-80 with low testosterone and established or high risk for cardiovascular disease. The trial found no increased incidence of major adverse cardiovascular events (MACE) with testosterone treatment compared to placebo, effectively addressing a longstanding safety concern.
The Considerations and Risks
Polycythemia (Elevated Red Blood Cells)
The most common adverse effect of TRT is an increase in red blood cell production (erythrocytosis). Testosterone stimulates erythropoiesis through multiple mechanisms, including direct stimulation of erythroid progenitor cells and increased erythropoietin production. Hematocrit levels above 54% increase blood viscosity and may elevate the risk of thromboembolic events.
Management strategies include regular monitoring (every 3-6 months), dose adjustment, changing administration route (topical tends to cause less erythrocytosis than injections), therapeutic phlebotomy, or blood donation. Most cases are manageable with appropriate monitoring and protocol adjustment.
Fertility Suppression
Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis via negative feedback, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. This leads to decreased intratesticular testosterone levels and impaired spermatogenesis. In many men, TRT effectively functions as male contraception.
This effect is generally reversible upon discontinuation, but recovery time varies (typically 6-12 months, sometimes longer). Men who wish to preserve fertility should discuss alternatives with their provider before starting TRT, such as selective estrogen receptor modulators (SERMs) like clomiphene, which stimulate endogenous testosterone production without suppressing sperm production.
Acne and Skin Changes
Testosterone increases sebaceous gland activity and sebum production, which can lead to acne, particularly on the back and shoulders. This effect is dose-dependent and more common in the initial months of therapy. Management includes topical treatments, dose adjustment, and in some cases, dermatological intervention.
Sleep Apnea
TRT may exacerbate pre-existing obstructive sleep apnea (OSA). The mechanism is thought to involve testosterone's effects on upper airway muscle tone and central respiratory drive. Screening for sleep apnea before starting TRT is recommended, and patients with known OSA should be monitored closely. In some cases, CPAP therapy can effectively manage OSA while continuing TRT.
Estradiol Elevation
Testosterone is converted to estradiol by the aromatase enzyme, which is predominantly expressed in adipose tissue. Men with higher body fat percentages may experience excessive aromatization, leading to elevated estradiol levels that can cause gynecomastia (breast tissue growth), water retention, and mood changes. Monitoring estradiol levels and using aromatase management strategies when indicated can address this issue.
Prostate Considerations
The historical concern that testosterone fuels prostate cancer has been largely reevaluated. The "saturation model" proposed by Morgentaler demonstrates that prostate tissue androgen receptors become saturated at relatively low testosterone levels (approximately 250 ng/dL), meaning that raising testosterone above this threshold does not incrementally increase prostate stimulation. Large observational studies and the TRAVERSE trial have not shown an increased incidence of prostate cancer with TRT.
However, TRT is still contraindicated in men with active prostate cancer, and baseline PSA screening is recommended before initiation. Men with elevated PSA or an abnormal digital rectal exam should be evaluated by a urologist before starting therapy.
Dependency and HPG Axis Suppression
Once exogenous testosterone is administered, the HPG axis downregulates endogenous production. If TRT is discontinued, there will be a period of low testosterone until the axis recovers, which can take weeks to months depending on the duration of therapy and individual factors. Some men may not fully recover baseline production, particularly after prolonged use. This means TRT is typically a long-term or lifelong commitment.
Making an Informed Decision
The decision to begin TRT should be based on a thorough evaluation that considers:
- Confirmed biochemical testosterone deficiency (two morning measurements)
- Presence of clinical symptoms consistent with hypogonadism
- Absence of contraindications (active prostate cancer, uncontrolled polycythemia, severe untreated sleep apnea)
- Fertility goals and family planning status
- Cardiovascular risk profile
- Commitment to ongoing monitoring and follow-up
- Realistic expectations regarding outcomes and timeline
Optimizing TRT Protocols: Frequency and Route
The traditional TRT protocol of bi-weekly intramuscular injections (e.g., 200mg testosterone cypionate every 14 days) has been increasingly replaced by more frequent, lower-dose protocols that produce more stable serum testosterone levels. The rationale is straightforward: testosterone cypionate has a half-life of approximately 8 days. With bi-weekly dosing, levels peak 2-3 days after injection and then decline progressively, creating a "roller coaster" pattern where patients experience supraphysiological levels early in the cycle and potentially subtherapeutic levels at the nadir.
Modern protocols often use smaller doses administered more frequently — for example, 80-100mg every 3.5 days (twice weekly), or even 40-50mg every other day. These micro-dosing approaches maintain serum testosterone within a tighter range, potentially reducing side effects associated with peak levels (acne, mood swings, erythrocytosis) while maintaining consistent symptom relief.
Subcutaneous injection has emerged as a viable alternative to intramuscular injection. Studies by Al-Futaisi et al. and others have demonstrated that subcutaneous testosterone cypionate produces comparable serum levels to intramuscular injection with potentially more stable pharmacokinetics. The smaller needle gauge (typically 27-31 gauge) and ability to self-inject in areas like the abdomen or thigh have made this route increasingly popular among both patients and providers.
The Role of Ancillary Medications
Several ancillary medications are commonly used alongside TRT to manage specific effects:
- Anastrozole: A non-steroidal aromatase inhibitor used when estradiol levels rise excessively due to aromatization. Used judiciously, it prevents estrogen-related side effects without driving estradiol too low, which can negatively affect bone density, lipid profiles, and joint health.
- HCG (Human Chorionic Gonadotropin): Mimics LH to maintain intratesticular testosterone production and testicular volume during TRT. Commonly dosed at 250-500 IU 2-3 times per week. Particularly important for men who wish to preserve some degree of fertility or who experience testicular atrophy.
- Enclomiphene: A selective estrogen receptor modulator (SERM) that stimulates LH and FSH release, sometimes used as a monotherapy alternative to TRT for men with secondary hypogonadism, or as an adjunct to support endogenous production.
Conclusion
The evidence base for TRT has matured significantly. For men with confirmed hypogonadism and appropriate clinical indications, the benefits — including improved body composition, bone density, metabolic health, sexual function, and quality of life — are well-supported by randomized controlled trials. The risks, while real, are generally manageable with proper monitoring and protocol management.
The key to a successful TRT outcome is thorough diagnosis, qualified medical oversight, regular monitoring, and an honest assessment of individual risk factors and goals. It is neither a panacea nor a danger — it is a medical treatment that, like all treatments, must be individualized and carefully managed. The shift toward more frequent, lower-dose protocols and subcutaneous administration reflects an ongoing refinement of TRT practice driven by both clinical evidence and patient experience.
This article is for educational purposes only. All medical decisions regarding hormone therapy should be made in consultation with a qualified healthcare provider.
